B. Riley Reduces Earnings Estimates for ClearPoint Neuro

ClearPoint Neuro, Inc. (NASDAQ:CLPT) – Analysts at B. Riley lowered their FY2025 earnings per share (EPS) estimates for shares of ClearPoint Neuro in a note issued to investors on Sunday, November 9th. B. Riley analyst A. Schock now expects that the company will post earnings of ($0.85) per share for the year, down from their prior estimate of ($0.81). The consensus estimate for ClearPoint Neuro’s current full-year earnings is ($0.66) per share. B. Riley also issued estimates for ClearPoint Neuro’s Q4 2025 earnings at ($0.22) EPS, Q1 2026 earnings at ($0.22) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.16) EPS and FY2026 earnings at ($0.75) EPS.

Several other equities analysts have also recently weighed in on the company. Wall Street Zen raised ClearPoint Neuro from a “sell” rating to a “hold” rating in a report on Saturday, September 13th. Stifel Nicolaus upped their price objective on ClearPoint Neuro from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of ClearPoint Neuro in a research report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, ClearPoint Neuro presently has an average rating of “Moderate Buy” and a consensus price target of $19.67.

ClearPoint Neuro Trading Up 5.3%

Shares of CLPT stock opened at $17.40 on Wednesday. The company has a current ratio of 7.30, a quick ratio of 6.45 and a debt-to-equity ratio of 1.46. ClearPoint Neuro has a 12-month low of $9.76 and a 12-month high of $30.10. The stock has a market capitalization of $494.63 million, a P/E ratio of -21.48 and a beta of 1.28. The firm’s 50 day moving average is $19.58 and its 200 day moving average is $14.58.

ClearPoint Neuro (NASDAQ:CLPT) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). ClearPoint Neuro had a negative return on equity of 94.44% and a negative net margin of 66.15%.The company had revenue of $5.36 million during the quarter, compared to the consensus estimate of $9.60 million. ClearPoint Neuro has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Financial Management Professionals Inc. bought a new stake in ClearPoint Neuro during the 3rd quarter worth approximately $28,000. Allworth Financial LP increased its stake in shares of ClearPoint Neuro by 3,076.9% in the second quarter. Allworth Financial LP now owns 2,065 shares of the company’s stock worth $25,000 after purchasing an additional 2,000 shares in the last quarter. BNP Paribas Financial Markets raised its position in shares of ClearPoint Neuro by 2,435.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,231 shares of the company’s stock valued at $27,000 after purchasing an additional 2,143 shares during the period. Ameritas Investment Partners Inc. bought a new stake in shares of ClearPoint Neuro during the 2nd quarter valued at $32,000. Finally, Legal & General Group Plc purchased a new position in shares of ClearPoint Neuro during the 2nd quarter valued at $35,000. 30.08% of the stock is currently owned by institutional investors.

Insider Transactions at ClearPoint Neuro

In other ClearPoint Neuro news, CEO Joseph Burnett sold 26,463 shares of the company’s stock in a transaction dated Friday, October 10th. The stock was sold at an average price of $26.98, for a total value of $713,971.74. Following the completion of the sale, the chief executive officer owned 217,059 shares in the company, valued at $5,856,251.82. This represents a 10.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 6.97% of the company’s stock.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.